Lisata Therapeutics Inc.
$ 3.37
-15.96%
16 Apr - close price
- Market Cap 30,438,800 USD
- Current Price $ 3.37
- High / Low $ 3.83 / 3.29
- Stock P/E N/A
- Book Value 1.68
- EPS -1.91
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.76 %
- 52 Week High 5.07
- 52 Week Low 1.81
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
Analyst Target Price
$9.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-01 | 2024-08-12 | 2024-05-09 | 2024-02-29 | 2023-11-02 | 2023-08-14 | 2023-05-09 |
| Reported EPS | -0.3344 | -0.49 | -0.54 | -0.55 | -0.55 | -0.59 | -0.61 | -0.65 | -0.66 | -0.65 | -0.5 | -0.77 |
| Estimated EPS | -0.625 | -0.59 | -0.64 | -0.53 | -0.76 | -0.77 | -0.76 | -0.72 | -0.89 | -0.93 | -0.7 | -0.81 |
| Surprise | 0.2906 | 0.1 | 0.1 | -0.02 | 0.21 | 0.18 | 0.15 | 0.07 | 0.23 | 0.28 | 0.2 | 0.04 |
| Surprise Percentage | 46.496% | 16.9492% | 15.625% | -3.7736% | 27.6316% | 23.3766% | 19.7368% | 9.7222% | 25.8427% | 30.1075% | 28.5714% | 4.9383% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LSTA
2026-04-16 06:40:25
Lisata Therapeutics (LSTA) has announced that Kuva Labs has not yet started the agreed-upon tender offer and is looking for new financing with better terms. The deadline for the tender offer was extended to April 13, 2026, but it has not commenced, and there is no guarantee it will proceed. Lisata is currently discussing the situation with Kuva Labs.
2026-04-15 20:39:04
Lisata Therapeutics and Kuva Labs have extended the deadline for Kuva's subsidiary to launch a tender offer to acquire all outstanding Lisata common shares to April 13, 2026. This delay is due to Kuva still seeking more favorable financing, and there is no assurance that the tender offer will commence. Lisata advises investors to review official SEC filings carefully before making any decisions regarding the potential tender offer.
2026-04-15 19:39:03
Lisata Therapeutics (LSTA) has reported that Kuva Labs Inc. has not yet initiated its planned tender offer to acquire Lisata's common shares, with the previously extended deadline of April 13, 2026, having passed. Kuva is reportedly seeking more favorable financing, injecting significant uncertainty into the acquisition. Lisata explicitly warns there is no guarantee the tender offer will commence or the transaction will close, raising concerns about deal risk and potential termination fees.
2026-04-13 01:38:43
This article announces that Lisata Therapeutics will be acquired by Kuva Labs for $4.00 per share in an all-cash transaction. The deal indicates a significant development for both companies' futures.
2026-04-04 22:40:49
Intellectia AI recommends "Hold" for Lisata Therapeutics Inc (LSTA) due to mixed technical indicators and significant declines in revenue and net income in Q4 2025. While moving averages are bullish, the negative MACD and weak financial performance suggest it's not a strong buy opportunity for long-term investors. A recent analyst rating from Brookline, however, maintained a "Buy" rating and raised the price target to $32, citing extended patent protection.
2026-04-03 13:39:48
Lisata Therapeutics Inc. and Kuva Labs have extended their equity acquisition offer deadline to April 13, 2026, as per a U.S. SEC filing. This extension allows more time for potential investors to assess the acquisition and reflects the parties' intent to finalize the agreement. The decision likely stems from various factors like market conditions or investor feedback, though no specific changes to terms have been disclosed.
